169 related articles for article (PubMed ID: 15905710)
1. The case for using 5-aminosalicyclates in Crohn's disease: pro.
Hanauer SB
Inflamm Bowel Dis; 2005 Jun; 11(6):609-12. PubMed ID: 15905710
[TBL] [Abstract][Full Text] [Related]
2. Debate: should mesalamine be used in Crohn's disease?: comments and conclusions.
Kamm MA
Inflamm Bowel Dis; 2005 Jun; 11(6):616-7. PubMed ID: 15905712
[TBL] [Abstract][Full Text] [Related]
3. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease.
Feagan BG
Eur J Surg; 1998 Dec; 164(12):903-9. PubMed ID: 10029385
[No Abstract] [Full Text] [Related]
4. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Hanauer S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
[TBL] [Abstract][Full Text] [Related]
5. The case against using 5-aminosalicyclates in Crohn's disease: con.
Stange EF
Inflamm Bowel Dis; 2005 Jun; 11(6):613-5. PubMed ID: 15905711
[No Abstract] [Full Text] [Related]
6. Mesalamine derivatives in the treatment of Crohn's disease.
Harrell LE; Hanauer SB
Gastroenterol Clin North Am; 2004 Jun; 33(2):303-17, ix-x. PubMed ID: 15177540
[TBL] [Abstract][Full Text] [Related]
7. [Ulcerous colitis and Crohn's disease in members of one family: case description and review of literature].
Neĭman KP; Rumiantsev VG
Eksp Klin Gastroenterol; 2006; (3):56-60. PubMed ID: 17203844
[No Abstract] [Full Text] [Related]
8. [5-aminosalicylic acid for induction of remission or clinical response in Crohn's disease--a survey of a Cochrane review].
Bjerrum JT; Munck LK; Nielsen OH
Ugeskr Laeger; 2011 Aug; 173(35):2110-3. PubMed ID: 21884660
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis.
Ford AC; Kane SV; Khan KJ; Achkar JP; Talley NJ; Marshall JK; Moayyedi P
Am J Gastroenterol; 2011 Apr; 106(4):617-29. PubMed ID: 21407190
[TBL] [Abstract][Full Text] [Related]
10. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
Bonapace CR; Mays DA
Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
Coward S; Kuenzig ME; Hazlewood G; Clement F; McBrien K; Holmes R; Panaccione R; Ghosh S; Seow CH; Rezaie A; Kaplan GG
Inflamm Bowel Dis; 2017 Mar; 23(3):461-472. PubMed ID: 28146003
[TBL] [Abstract][Full Text] [Related]
12. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
Feagan BG; Sandborn WJ
Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
[TBL] [Abstract][Full Text] [Related]
13. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
14. Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.
Sandborn WJ; Feagan BG
Aliment Pharmacol Ther; 2003 Aug; 18(3):263-77. PubMed ID: 12895211
[TBL] [Abstract][Full Text] [Related]
15. 5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion.
Feagan BG
Clin Gastroenterol Hepatol; 2004 May; 2(5):376-8. PubMed ID: 15118974
[No Abstract] [Full Text] [Related]
16. Mesalamine for prophylaxis of small bowel Crohn's disease recurrence.
Bauer WM; Brzezinski A; Lashner BA
Curr Gastroenterol Rep; 1999 Oct; 1(5):377-83. PubMed ID: 10980975
[TBL] [Abstract][Full Text] [Related]
17. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease.
Doherty G; Katsanos KH; Burisch J; Allez M; Papamichael K; Stallmach A; Mao R; Berset IP; Gisbert JP; Sebastian S; Kierkus J; Lopetuso L; Szymanska E; Louis E
J Crohns Colitis; 2018 Jan; 12(1):17-31. PubMed ID: 28981623
[TBL] [Abstract][Full Text] [Related]
18. Drug insight: aminosalicylates for the treatment of IBD.
Nielsen OH; Munck LK
Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
[TBL] [Abstract][Full Text] [Related]
19. Controversies with aminosalicylates in inflammatory bowel disease.
Lim WC; Hanauer SB
Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
[TBL] [Abstract][Full Text] [Related]
20. Mesalamine in the treatment of active Crohn's disease.
Dignass A; Marteau P
Gastroenterology; 2005 Jan; 128(1):245-6; author reply 246. PubMed ID: 15633152
[No Abstract] [Full Text] [Related]
[Next] [New Search]
